Q2 Earnings Forecast for IO Biotech Issued By HC Wainwright

IO Biotech, Inc. (NASDAQ:IOBT) – Analysts at HC Wainwright boosted their Q2 2025 EPS estimates for shares of IO Biotech in a research report issued on Wednesday, May 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.38) per share for the quarter, up from their prior forecast of ($0.51). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IO Biotech’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.25) EPS and FY2029 earnings at $0.03 EPS.

Separately, Piper Sandler raised shares of IO Biotech to a “strong-buy” rating in a report on Wednesday, March 12th.

IO Biotech Price Performance

Shares of NASDAQ:IOBT opened at $1.03 on Monday. IO Biotech has a 1-year low of $0.66 and a 1-year high of $1.73. The stock has a market cap of $67.86 million, a P/E ratio of -0.75 and a beta of 0.09. The firm has a fifty day moving average price of $0.97 and a 200 day moving average price of $0.93.

Hedge Funds Weigh In On IO Biotech

A number of large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of IO Biotech in the first quarter valued at about $26,000. XTX Topco Ltd acquired a new stake in IO Biotech in the fourth quarter valued at about $26,000. Vontobel Holding Ltd. purchased a new stake in IO Biotech in the 4th quarter valued at approximately $30,000. Renaissance Technologies LLC increased its position in IO Biotech by 22.5% during the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock worth $109,000 after purchasing an additional 21,800 shares during the period. Finally, Citadel Advisors LLC acquired a new position in IO Biotech during the 4th quarter worth approximately $249,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.